This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Jan 2014

Canbex Therapeuti?cs Ltd to Present at Biotech Showcase 2014

Canbex Therapeutics Ltd announced today that Dr Jesse Schulman, Chief Executive Officer of Canbex, will be presenting at the Biotech Showcase 2014 Conference being held in San Francisco, CA.


Details of Canbex Therapeutic Ltd’s presentation are as follows:

Event: Biotech Showcase 2014 Conference
Date: Tuesday 14 January 2014
Time: 9.30 am
Location: B-Mission I (4th Floor) Parc 55 Wyndham San Francisco Union Square Hotel


The presentation will outline recent progress of its novel, orally active lead compound aimed at changing the treatment of spasticity in patients with multiple sclerosis through improved tolerability.


Canbex reports that its Phase I clinical trial of lead compound VSN16R is progressing well and according to plan. “The superior tolerability of VSN16R is supported by our clinical results to date,” commented Canbex CEO Dr Jesse Schulman. “In addition, the pharmacokinetic data suggest that a patient-friendly dosing regime can be achieved, which would also be a significant advantage.”


Canbex’s Phase I trial to study the safety, tolerability and pharmacokinetics of VSN16R is being conducted by Quintiles, the world’s largest clinical research organisation, and will enrol up to 72 subjects.


Dr Keith Powell, Chairman of Canbex, said: “Canbex is delighted that it was selected to present the VSN16R story at the Biotech Showcase, a leading event for the life sciences industry and investors. We believe that VSN16R offers a commercial and investment opportunity with life-changing potential for people with multiple sclerosis.”


“With good safety and tolerability results so far, Canbex and its world-leading clinical advisors are preparing for a Phase II clinical trial to study the compound’s efficacy,” Dr Powell added.


Canbex believes that VSN16R has the potential to become an important advance in the treatment of spasticity, a condition for which there remains a substantial unmet medical need. Spasticity is characterised by sudden and uncontrollable movements of limb and torso musculature, and is among the most painful, damaging and debilitating symptoms of multiple sclerosis. Current drug treatments have a high level of undesirable side effects, particularly sedation and cognitive dysfunction. Many patients cannot tolerate current treatments, and so are treated with palliative measures alone, or with drug regimes that result in poor quality of life.

Related News